SCHEMBL15224271

SCHEMBL15224271

CN(Cc1cccc2ccccc12)C(=O)CCCN

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.56
MC5R P33032 1/20 0.56
MC3R P41968 1/20 0.56
MC1R Q01726 1/20 0.56
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
METAP2 P50579 8/20 0.49
METAP1 P53582 4/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15224110 0.93 CYP1A2 (0.56) MC4RMC5RMC3RMC1RCYP1A2
SCHEMBL15224270 0.84 CYP1A2 (0.53) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL15224109 0.80 CYP1A2 (0.54) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL416348 0.78 METAP2 (0.43) MC4RMC5RMC3RMC1RCYP1A2
SCHEMBL23972323 0.77 CYP1A2 (0.62) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL8303717 0.77 MC4R (0.51) MC4RMC5RMC3RMC1RCYP1A2
SCHEMBL9240681 0.75 TACR1 (0.54) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL26027575 0.75 METAP2 (0.62) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL5713026 0.74 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19METAP2METAP1
SCHEMBL5647636 0.74 PDK1 (0.57) CYP1A2CYP2D6CYP2C19METAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MC4R 1091/4885MC5R 657/4885MC3R 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.